Arcutis Q3 2026: Revenue Rose 45% While EPS Missed Expectations

As seen on the 24/7 Wall St. homepage on November 4, 2026.

ARQT Arcutis Biotherapeutics
Q3 2026
EPS
$0.06
est $0.17 -64.3%
Revenue
$144M
est $143M +0.9%

Arcutis missed EPS expectations because SG&A jumped to $99.6 million from $62.4 million a year ago to fund a new primary care and pediatric sales force. Revenue still grew 45% and management raised full-year net product sales guidance to $535 million to $545 million, with an FDA decision on ZORYVE cream for infants due February 23, 2027.

Continue ReadingShow less

Arcutis posted Q3 2026 revenue of $143.9 million, meeting expectations and marking a 45% jump from the same period a year earlier. The growth came almost entirely from rising unit demand across the ZORYVE roflumilast franchise.

The earnings picture was far messier. GAAP EPS came in at $0.06, missing expectations, and the culprit was a sharp rise in selling, general and administrative expenses. That increase funded the rollout of a new primary care and pediatric sales team and an expanded consumer awareness campaign, including a partnership with gymnast Simone Biles under a campaign called Skin to Believe In.

Despite the EPS shortfall, the underlying profit picture held up. Net income grew to $8.8 million, and operating cash flow stayed positive for the quarter. Shareholders' equity expanded 54% year over year, suggesting the sales force buildout is being absorbed without destabilizing the balance sheet.

Sponsored

Management responded to the quarter by raising full-year 2026 net product sales guidance to $535 million to $545 million, up from the prior range of $525 million to $540 million. CEO Frank Watanabe pointed to continued prescription momentum and called out what he sees as the company's next major growth lever, an FDA decision on ZORYVE cream 0.05% for infants as young as 3 months, with a target action date of February 23, 2027.

That infant-label decision is the clearest near-term event for investors to monitor. The company also expects topline Phase 2 vitiligo data for ZORYVE foam 0.3% and a program advancement decision by year-end 2026, and Phase 2 hidradenitis suppurativa results in Q1 2027. How the FDA rules on the infant indication will likely set the tone for how the market weighs the ongoing expense ramp against the franchise's long-term reach.

Mentioned: ARQT